Randomized trial · people
Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In adults with MASH and stage 2-3 scarring, efinopegdutide cleared MASH in far more people than placebo over a year, and side effects were most common at 10 mg.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 381
- Published
- 2026
- Journal
- Lancet
What they tested
The team tested whether weekly efinopegdutide could clear MASH and reduce liver scarring in adults without cirrhosis, compared with placebo.
How the study was done
A phase 2b, randomized, double-blind, placebo-controlled trial at 176 centers in 26 countries. Of 386 adults randomized, 381 received at least one dose. All had biopsy-confirmed MASH (fatty liver with inflammation) and stage 2 or stage 3 fibrosis (scarring). They got weekly shots of efinopegdutide 4 mg, 7 mg or 10 mg, placebo (a dummy shot), or open-label semaglutide 2.4 mg for 52 weeks.

What they found
At week 52, MASH went away without fibrosis getting worse in 31 of 55 people (56%) in the 4 mg arm, 31 of 49 (63%) in the 7 mg arm and 35 of 57 (61%) in the 10 mg arm, compared with 7 of 53 (13%) on placebo. Gaps versus placebo were 43.0, 49.5 and 47.8 percentage points, all p<0.0001. On semaglutide, 26 of 49 (53%) met this goal. Fibrosis improved by at least one stage without worse inflammation in 43% (4 mg), 52% (7 mg) and 34% (10 mg) versus 21% on placebo. The 10 mg result did not reach statistical significance (p=0.072). Gut side effects were the most common, and they were highest at 10 mg. At 10 mg, 11% stopped treatment due to side effects, versus 3-4% at the lower doses and 1% on placebo.
What it doesn’t show
This was a mid-stage trial that lasted 1 year. It does not show longer-term liver outcomes. The semaglutide arm was open-label, and the trial was funded by Merck Sharp & Dohme.
The paper
Lawitz et al. Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. Lancet. 2026.
The compound
More studies on Efinopegdutide
- Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutideRandomized trial · people · 2023
- Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeksRandomized trial · people · 2021
- Every study on Efinopegdutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.